Joseph R. Nevins – Publications

research  •  publications

Representative Publications:

FOXO Transcription Factors Control E2F1 Transcriptional Specificity and Apoptotic Function.
Shats I, Gatza ML, Liu B, Angus SP, You L, Nevins J, Cancer Res. 2013 Aug 21;. Abstract

Interaction of E2F7 Transcription Factor with E2F1 and C-terminal-binding Protein (CtBP) Provides a Mechanism for E2F7-dependent Transcription Repression.
Liu B, Shats I, Angus SP, Gatza ML, Nevins JR, J Biol Chem. 2013 Aug 23;288(34):24581-9. Abstract

E2F6 associates with BRG1 in transcriptional regulation.
Leung JY, Nevins JR, PLoS One. 2012;7(10):e47967. Abstract

A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest.
Angus SP, Nevins JR, Oncogene. 2012 Nov 1;31(44):4709-17. Abstract

SIGNATURE: a workbench for gene expression signature analysis.
Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P, Nevins JR, BMC Bioinformatics. 2011;12:443. Abstract

Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.
Leung JY, Andrechek ER, Cardiff RD, Nevins JR, Oncogene. 2012 May 17;31(20):2545-54. Abstract

Network calisthenics: control of E2F dynamics in cell cycle entry.
Wong JV, Dong P, Nevins JR, Mathey-Prevot B, You L, Cell Cycle. 2011 Sep 15;10(18):3086-94. Abstract

Peripheral blood signatures of lead exposure.
LaBreche HG, Meadows SK, Nevins JR, Chute JP, PLoS One. 2011;6(8):e23043. Abstract

Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors.
LaBreche HG, Nevins JR, Huang E, BMC Med Genomics. 2011;4:61. Abstract

A methodology for utilization of predictive genomic signatures in FFPE samples.
Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR, BMC Med Genomics. 2011;4:58. Abstract

Use of gene expression and pathway signatures to characterize the complexity of human melanoma.
Freedman JA, Tyler DS, Nevins JR, Augustine CK, Am J Pathol. 2011 Jun;178(6):2513-22. Abstract

Using noisy gene expression mediated by engineered adenovirus to probe signaling dynamics in mammalian cells.
Wong JV, Yao G, Nevins JR, You L, Methods Enzymol. 2011;497:221-37. Abstract

Pathway-based classification of lung cancer: a strategy to guide therapeutic selection.
Nevins JR, Proc Am Thorac Soc. 2011 May;8(2):180-2. Abstract

Origin of bistability underlying mammalian cell cycle entry.
Yao G, Tan C, West M, Nevins JR, You L, Mol Syst Biol. 2011 Apr 26;7:485. Abstract

Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC.
Wong JV, Yao G, Nevins JR, You L, Mol Cell. 2011 Feb 4;41(3):275-85. Abstract

Using a stem cell-based signature to guide therapeutic selection in cancer.
Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR, Cancer Res. 2011 Mar 1;71(5):1772-80. Abstract

Stochastic E2F activation and reconciliation of phenomenological cell-cycle models.
Lee TJ, Yao G, Bennett DC, Nevins JR, You L, PLoS Biol. 2010;8(9). Abstract

Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles.
Meadows SK, Dressman HK, Daher P, Himburg H, Russell JL, Doan P, Chao NJ, Lucas J, Nevins JR, Chute JP, PLoS One. 2010;5(7):e11535. Abstract

Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies.
Andrechek ER, Nevins JR, J Mol Med (Berl). 2010 Nov;88(11):1095-100. Abstract

Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate.
Kim JW, Mori S, Nevins JR, Cancer Res. 2010 Jun 15;70(12):4820-8. Abstract

Refocusing the war on cancer: the critical role of personalized treatment.
Potti A, Schilsky RL, Nevins JR, Sci Transl Med. 2010 Apr 21;2(28):28cm13. Abstract

Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.
Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB, J Clin Oncol. 2010 May 1;28(13):2198-206. Abstract

A pathway-based classification of human breast cancer.
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR, Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. Abstract

Age- and sex-specific genomic profiles in non-small cell lung cancer.
Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, Lamlertthon W, Barry W, Crawford J, Nevins J, Potti A, JAMA. 2010 Feb 10;303(6):535-43. Abstract

Multimodal regulation of E2F1 gene expression by progestins.
Wade HE, Kobayashi S, Eaton ML, Jansen MS, Lobenhofer EK, Lupien M, Geistlinger TR, Zhu W, Nevins JR, Brown M, Otteson DC, McDonnell DP, Mol Cell Biol. 2010 Apr;30(8):1866-77. Abstract

A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, Diehl LF, Decastro CM, Potti A, Nevins JR, Clin Cancer Res. 2009 Nov 15;15(22):6947-55. Abstract

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.
Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR, Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16387-92. Abstract

A role for E2F activities in determining the fate of Myc-induced lymphomagenesis.
Rempel RE, Mori S, Gasparetto M, Glozak MA, Andrechek ER, Adler SB, Laakso NM, Lagoo AS, Storms R, Smith C, Nevins JR, PLoS Genet. 2009 Sep;5(9):e1000640. Abstract

Utilization of genomic signatures to identify phenotype-specific drugs.
Mori S, Chang JT, Andrechek ER, Potti A, Nevins JR, PLoS One. 2009;4(8):e6772. Abstract

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM, Breast Cancer Res. 2009;11(4):R55. Abstract

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD, Potti A, J Clin Oncol. 2009 Sep 1;27(25):4197-203. Abstract

A combinatorial mechanism for determining the specificity of E2F activation and repression.
Freedman JA, Chang JT, Jakoi L, Nevins JR, Oncogene. 2009 Aug 13;28(32):2873-81. Abstract

Anchorage-independent cell growth signature identifies tumors with metastatic potential.
Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR, Oncogene. 2009 Aug 6;28(31):2796-805. Abstract

A genomic strategy to elucidate modules of oncogenic pathway signaling networks.
Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR, Mol Cell. 2009 Apr 10;34(1):104-14. Abstract

Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.
Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A, Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7. Abstract

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA, Breast Cancer Res Treat. 2009 Dec;118(3):635-43. Abstract

Balancing the decision of cell proliferation and cell fate.
Hallstrom TC, Nevins JR, Cell Cycle. 2009 Feb 15;8(4):532-5. Abstract

Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS, Clin Cancer Res. 2009 Jan 15;15(2):502-10. Abstract

The genomic analysis of lactic acidosis and acidosis response in human cancers.
Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, Dewhirst M, West M, Chi JT, PLoS Genet. 2008 Dec;4(12):e1000293. Abstract

High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics.
Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang Q, West M, J Am Stat Assoc. 2008 Dec 1;103(484):1438-1456. Abstract

Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.
Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, Potti A, Bild A, Nevins JR, Cancer Res. 2008 Oct 15;68(20):8525-34. Abstract

A genomic approach to identify molecular pathways associated with chemotherapy resistance.
Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG, Mol Cancer Ther. 2008 Oct;7(10):3141-9. Abstract

Toward the individualization of lung cancer therapy.
Anguiano A, Nevins JR, Potti A, Cancer. 2008 Oct 1;113(7 Suppl):1760-7. Abstract

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL, J Clin Oncol. 2008 Jul 10;26(20):3324-30. Abstract

Patterns of cell signaling pathway activation that characterize mammary development.
Andrechek ER, Mori S, Rempel RE, Chang JT, Nevins JR, Development. 2008 Aug;135(14):2403-13. Abstract

Sensing and integration of Erk and PI3K signals by Myc.
Lee T, Yao G, Nevins J, You L, PLoS Comput Biol. 2008 Feb;4(2):e1000013. Abstract

An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer.
Xu M, Kao MC, Nunez-Iglesias J, Nevins JR, West M, Zhou XJ, BMC Genomics. 2008;9 Suppl 1:S12. Abstract

Gene expression signatures of radiation response are specific, durable and accurate in mice and humans.
Meadows SK, Dressman HK, Muramoto GG, Himburg H, Salter A, Wei Z, Ginsburg GS, Ginsburg G, Chao NJ, Nevins JR, Chute JP, PLoS One. 2008;3(4):e1912. Abstract

A bistable Rb-E2F switch underlies the restriction point.
Yao G, Lee TJ, Mori S, Nevins JR, You L, Nat Cell Biol. 2008 Apr;10(4):476-82. Abstract

A role for Myc in facilitating transcription activation by E2F1.
Leung JY, Ehmann GL, Giangrande PH, Nevins JR, Oncogene. 2008 Jul 10;27(30):4172-9. Abstract

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A, PLoS One. 2008;3(1):e1373. Abstract

An E2F1-dependent gene expression program that determines the balance between proliferation and cell death.
Hallstrom TC, Mori S, Nevins JR, Cancer Cell. 2008 Jan;13(1):11-22. Abstract

New breast cancer genes-discovery at the intersection of complex data sets.
Nevins JR, Cancer Cell. 2007 Dec;12(6):497-9. Abstract

Phylogenetic simulation of promoter evolution: estimation and modeling of binding site turnover events and assessment of their impact on alignment tools.
Huang W, Nevins JR, Ohler U, Genome Biol. 2007;8(10):R225. Abstract

Genomic strategies for personalized cancer therapy.

Garman KS, Nevins JR, Potti A, Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32. Abstract

Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.
Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER, Layzer JM, Keys JR, Hagen PO, Nevins JR, Koch WJ, Sullenger BA, Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):12988-93. Abstract

Mining gene expression profiles: expression signatures as cancer phenotypes.
Nevins JR, Potti A, Nat Rev Genet. 2007 Aug;8(8):601-9. Abstract

Gene expression signatures that predict radiation exposure in mice and humans.
Dressman HK, Muramoto GG, Chao NJ, Meadows S, Marshall D, Ginsburg GS, Nevins JR, Chute JP, PLoS Med. 2007 Apr;4(4):e106. Abstract

Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.
Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A, Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1733-45. Abstract

Genomic prediction of locoregional recurrence after mastectomy in breast cancer.
Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, Dressman H, Chen CM, Tsai SY, Jian JJ, Liu MC, Nevins JR, Huang AT, J Clin Oncol. 2006 Oct 1;24(28):4594-602. Abstract

GATHER: a systems approach to interpreting genomic signatures.
Chang JT, Nevins JR, Bioinformatics. 2006 Dec 1;22(23):2926-33. Abstract

Linking oncogenic pathways with therapeutic opportunities.
Bild AH, Potti A, Nevins JR, Nat Rev Cancer. 2006 Sep;6(9):735-41. Abstract

Compensation and specificity of function within the E2F family.
Kong LJ, Chang JT, Bild AH, Nevins JR, Oncogene. 2007 Jan 18;26(3):321-7. Abstract

Embracing the complexity of genomic data for personalized medicine.
West M, Ginsburg GS, Huang AT, Nevins JR, Genome Res. 2006 May;16(5):559-66. Abstract

The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1.
Kong LJ, Meloni AR, Nevins JR, Mol Cell. 2006 Apr 7;22(1):63-71. Abstract

Jab1 is a specificity factor for E2F1-induced apoptosis.
Hallstrom TC, Nevins JR, Genes Dev. 2006 Mar 1;20(5):613-23. Abstract

Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.
Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones EL, Vujaskovic Z, Marks J, Dewhirst MW, West M, Nevins JR, Blackwell K, Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26. Abstract

Molecular evidence for arterial repair in atherosclerosis.
Karra R, Vemullapalli S, Dong C, Herderick EE, Song X, Slosek K, Nevins JR, West M, Goldschmidt-Clermont PJ, Seo D, Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16789-94. Abstract

Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR, Nature. 2006 Jan 19;439(7074):353-7. Abstract

A mechanism of COOH-terminal binding protein-mediated repression.
Meloni AR, Lai CH, Yao TP, Nevins JR, Mol Cancer Res. 2005 Oct;3(10):575-83. Abstract

Distinctions in the specificity of E2F function revealed by gene expression signatures.
Black EP, Hallstrom T, Dressman HK, West M, Nevins JR, Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15948-53. Abstract

Gene expression profiling and genetic markers in glioblastoma survival.
Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M, Cancer Res. 2005 May 15;65(10):4051-8. Abstract

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR, Clin Cancer Res. 2005 May 15;11(10):3686-96. Abstract

Temporal control of cell cycle gene expression mediated by E2F transcription factors.
Zhu W, Giangrande PH, Nevins JR, Cell Cycle. 2005 May;4(5):633-6. Abstract

DIG–a system for gene annotation and functional discovery.
Delong M, Yao G, Wang Q, Dobra A, Black EP, Chang JT, Bild A, West M, Nevins JR, Dressman H, Bioinformatics. 2005 Jul 1;21(13):2957-9. Abstract

A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription.
Giangrande PH, Zhu W, Schlisio S, Sun X, Mori S, Gaubatz S, Nevins JR, Genes Dev. 2004 Dec 1;18(23):2941-51. Abstract

E2Fs link the control of G1/S and G2/M transcription.
Zhu W, Giangrande PH, Nevins JR, EMBO J. 2004 Nov 24;23(23):4615-26. Abstract

Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes.
Pittman J, Huang E, Nevins J, Wang Q, West M, Biostatistics. 2004 Oct;5(4):587-601. Abstract

An overview of genomic data analysis.
Huang ES, Nevins JR, West M, Kuo PC, Surgery. 2004 Sep;136(3):497-9. Abstract

Gene expression phenotypes of atherosclerosis.
Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, Dong C, Vata K, Milano CA, Rigat F, Pittman J, Nevins JR, West M, Goldschmidt-Clermont PJ, Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1922-7. Abstract

Evolving strategies for targeted cancer therapy–past, present, and future.
Wells SA, Nevins JR, J Natl Cancer Inst. 2004 Jul 7;96(13):980-1. Abstract

Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes.
Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR, West M, Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8431-6. Abstract

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR, Am J Obstet Gynecol. 2004 Apr;190(4):910-25. Abstract

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.
Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR, Sears R, Nat Cell Biol. 2004 Apr;6(4):308-18. Abstract

Combinatorial gene control involving E2F and E Box family members.
Giangrande PH, Zhu W, Rempel RE, Laakso N, Nevins JR, EMBO J. 2004 Mar 24;23(6):1336-47. Abstract

Gene expression patterns that characterize advanced stage serous ovarian cancers.
Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A, J Soc Gynecol Investig. 2004 Jan;11(1):51-9. Abstract

The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells.
Cook JG, Chasse DA, Nevins JR, J Biol Chem. 2004 Mar 5;279(10):9625-33. Abstract

Gene expression phenotypes of oncogenic signaling pathways.
Huang ES, Black EP, Dressman H, West M, Nevins JR, Cell Cycle. 2003 Sep-Oct;2(5):415-7. Abstract

Specificity in the activation and control of transcription factor E2F-dependent apoptosis.
Hallstrom TC, Nevins JR, Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10848-53. Abstract

Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction.
Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M, Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R153-7. Abstract

Distinct gene expression phenotypes of cells lacking Rb and Rb family members.
Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL, Ishida S, West M, Nevins JR, Cancer Res. 2003 Jul 1;63(13):3716-23. Abstract

Gene expression profiling for prediction of clinical characteristics of breast cancer.
Huang E, West M, Nevins JR, Recent Prog Horm Res. 2003;58:55-73. Abstract

Gene expression phenotypic models that predict the activity of oncogenic pathways.
Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D’Amico M, Pestell RG, West M, Nevins JR, Nat Genet. 2003 Jun;34(2):226-30. Abstract

Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor.
Giangrande PH, Hallstrom TC, Tunyaplin C, Calame K, Nevins JR, Mol Cell Biol. 2003 Jun;23(11):3707-20. Abstract

Gene expression predictors of breast cancer outcomes.
Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT, Lancet. 2003 May 10;361(9369):1590-6. Abstract

Prediction and uncertainty in the analysis of gene expression profiles.
Spang R, Zuzan H, West M, Nevins J, Blanchette C, Marks JR, In Silico Biol. 2002;2(3):369-81. Abstract

Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function.
Schlisio S, Halperin T, Vidal M, Nevins JR, EMBO J. 2002 Nov 1;21(21):5775-86. Abstract

Optimizing aptamer activity for gene therapy applications using expression cassette SELEX.
Martell RE, Nevins JR, Sullenger BA, Mol Ther. 2002 Jul;6(1):30-4. Abstract

Analysis of Cdc6 function in the assembly of mammalian prereplication complexes.
Cook JG, Park CH, Burke TW, Leone G, DeGregori J, Engel A, Nevins JR, Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1347-52. Abstract

Signaling networks that link cell proliferation and cell fate.
Sears RC, Nevins JR, J Biol Chem. 2002 Apr 5;277(14):11617-20. Abstract